Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965072 | 0.88 | ABL1 (0.49) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1019941 | 0.86 | ALB (0.48) | — | |
| SCHEMBL12679591 | 0.81 | KMT2A (0.71) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12679606 | 0.81 | KMT2A (0.65) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9965099 | 0.80 | MCHR1 (0.57) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12681347 | 0.79 | KMT2A (0.59) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9965076 | 0.79 | KMT2A (0.52) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9965065 | 0.79 | KMT2A (0.48) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9965098 | 0.78 | HIF1A (0.57) | KMT2AMEN1POLBHTT | |
| SCHEMBL12679631 | 0.78 | ABL1 (0.58) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | SHH, NR4A2, NR4A3 | KMT2A 1167/4885MEN1 2776/4885CYP1A2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.